News | June 17, 2014

AtheroNova Receives Notice of Issuance of Second U.S. Patent

June 17, 2014 — AtheroNova Inc. received a Notice of Issuance for an additional compound for cardiovascular treatments. This patent issuance further exemplifies a plan to develop a broad platform of intellectual property involving atheroma stabilization and reduction, lipid modulation and other metabolic diseases. This issuance continues efforts by the company and its patent counsel in pursuit of numerous patents covering the systemic delivery of naturally occurring bile acids, bile acid synthetics, analogs and conjugates. AtheroNova is a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans.

"This latest patent issuance expands our patent portfolio to now include multiple compounds for addressing atherosclerotic plaque and stands as an important continuation of our goal of being the clear leader in the systemic delivery of bile acids, bile acid synthetics, analogs and conjugates to dramatically enhance cardiovascular and metabolic health," said AtheroNova CEO Thomas W. Gardner. "As our drug development efforts accelerate, the company will continue to pursue additional pending patent applications for systemic delivery of our family of bile acids and bile acid derivatives. The development of our platform is significantly advanced by this achievement."

For more information: www.atheronova.com

Related Content

Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals | October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals | September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals | September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Overlay Init